Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.
about
Immunotherapy for advanced renal cell cancerTargeted therapy for advanced renal cell carcinomaImmunotherapy for advanced renal cell cancerImmunotherapy for metastatic renal cell carcinoma.Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature.Rapid in vitro derivation of endothelium directly from human cancer cells.Drugs to suppress cough.Interferon alpha for the treatment of advanced renal cancer.Angiogenesis inhibitors in the treatment of cancer.Molecularly targeted therapy in renal cell carcinoma.Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review.Targeted approaches for treating advanced clear cell renal carcinoma.Therapeutic options to target angiogenesis in human malignancies.Kidney cancer therapy: new perspectives and avenues.Molecularly targeted therapy in renal cell carcinoma: where do we go from here?Anti-angiogenic therapy in renal cell cancer.Active and passive immunotherapy: vaccines and antibodies.Targeting the PI3K-Akt pathway in kidney cancer.Current status of cytoreductive nephrectomy in metastatic renal cell carcinoma.VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment.The von Hippel-Lindau gene: turning discovery into therapy.The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts.Using Molecular Biology to Develop Drugs for Renal Cell Carcinoma.Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies.Monoclonal antibodies in lung cancer.Targeting angiogenesis in renal cell carcinoma.Systemic therapy for patients with advanced, unresectable ormetastatic renal cell carcinoma: moving to guidelines.The bevacizumab experience in advanced renal cell carcinomaImproving gene transfer in human renal carcinoma cells: Utilization of adenovirus vectors containing chimeric type 5 and type 35 fiber proteins.Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.The biology of hypoxia: the role of oxygen sensing in development, normal function, and disease.Histological findings of uveal capillaries in rabbit eyes after multiple intravitreal injections of bevacizumab.Clinical response to therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: impact of patient characteristics and Von Hippel-Lindau gene status.Bevacizumab Diminishes Inflammation in an Acute Endotoxin-Induced Uveitis Model.An update on current management of advanced renal cell cancer, biomarkers, and future directions
P2860
Q24187300-8EA2CBD7-1652-43E9-8122-D52D969561D5Q24242946-8B52B320-86C9-48E2-91A1-458AE7C08568Q24246777-D993929C-DC3D-4309-82B5-127BEE03D697Q30234458-7FE87A3C-ED3A-426F-AAD5-042C560A2702Q31060162-00724CCB-BB3D-4CED-AB71-A103C21CC9F6Q35018915-E9BCE608-2686-4624-9984-4A9708648852Q36040853-538C22A9-3F5E-43F7-9F52-825E54831427Q36161207-88FCB046-152D-49A9-9AE9-6BEF4D388E24Q36222054-02255EBB-3EE6-4F31-9417-321BBE2C166BQ36334896-1D8EE38F-23F6-4903-92D3-CE3F6AFC6192Q36370992-C130AFD4-0FF2-4885-BDCA-8906B56729CEQ36594711-AD72EDF6-33E0-4EA5-A13C-3658D1A3CC2FQ36634261-B7F2B512-7F35-48DB-97ED-5A9106815803Q36675387-21B95F5B-2C06-4F3E-9A24-D844D03F2532Q36689144-E1267FB6-0033-4B0E-B777-AFB4DB200933Q36794815-1DBB266C-C2EE-4405-915F-3B6DFA8C9EC7Q36794818-CC5147DF-1AA2-48E3-B411-8235C8BCB16BQ36842782-AF7EB64A-9EEC-4F1A-B2EE-B326C3600C4CQ37025955-5E1F7DF0-B5B2-440D-A6D6-7CB0690665CBQ37038901-FFE9EA3A-1F53-46A8-A3BB-29A287E09F47Q37272653-2D7BFEEB-3508-4DD8-A794-F61A78F81053Q37458553-63C51272-8332-435D-842D-677171F41686Q37774569-7D0A7FC6-FB38-4C5C-9D87-606B4C86980CQ37846389-F03E4061-2C06-4D55-97C2-9030560714E7Q38067454-84025E56-826A-4D75-81C7-57C86F3E3234Q38132231-A40D50C9-286C-42D2-AC96-EF62CA70B906Q39021361-9A096A72-EDE8-4C53-882D-4E6278F726DBQ41899102-C81BC38E-96F3-4D70-B18B-8CB2C7FC54C8Q42326136-75F08A60-F7D6-4D76-85FC-6AF5FC3B7DCFQ42379480-D39ABD4D-7AA0-4F12-B213-E8061D998DF3Q42399153-BD449DD8-A9EA-4B4D-A258-6830433CB785Q45759035-67727ABF-F3B1-4D30-8E75-C64C71CCC992Q46014175-6D0FA985-E6D0-4F21-831F-3ECFEB50537EQ55412994-1081D8AE-EF64-4455-B35A-2061E0060C61Q56897121-983880BF-C879-400E-B35E-39FB835911BB
P2860
Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Cancer and Leukemia Group B 90 ...... tastatic renal cell carcinoma.
@en
Cancer and Leukemia Group B 90 ...... thelial growth factor antibody
@nl
type
label
Cancer and Leukemia Group B 90 ...... tastatic renal cell carcinoma.
@en
Cancer and Leukemia Group B 90 ...... thelial growth factor antibody
@nl
prefLabel
Cancer and Leukemia Group B 90 ...... tastatic renal cell carcinoma.
@en
Cancer and Leukemia Group B 90 ...... thelial growth factor antibody
@nl
P2093
P921
P1476
Cancer and Leukemia Group B 90 ...... tastatic renal cell carcinoma.
@en
P2093
Brian I Rini
Eric J Small
John Taylor
Richard L Schilsky
Susan Halabi
P304
P356
10.1158/1078-0432.CCR-03-0605
P407
P577
2004-04-01T00:00:00Z